A randomized, placebo-controlled phase III trial of an autologous, formalin-fixed tumor vaccine for newly diagnosed glioblastoma: trial protocol
Japanese Journal of Clinical Oncology · 2025
DOI: 10.1093/jjco/hyaf078 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Japanese Journal of Clinical Oncology, 2025. Verfasst von Yoshihiro Muragaki und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Device Engineering, Kobe University, Kusunoki-cho, Chuo-ku, Kobe City, Hyogo 650-0017, Japan. Hauptthemen laut MEDLINE: Glioblastoma, Cancer Vaccines, Brain Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
This multi-institutional, double-blind, randomized, placebo-controlled phase III trial was designed to evaluate the efficacy and safety of Cellm-001, an autologous formalin-fixed brain tumor immunostimulant, for newly diagnosed glioblastoma with gross total resection to prolong overall survival (OS) and prevent recurrence after surgery. One hundred twelve patients are to be randomized 1:1 to either Cellm-001 with standard chemoradiotherapy (CRT) or saline solution with standard CRT. Randomization is based on the following stratified randomization criteria: age, Karnofsky Performance Status, and the presence or absence of photodynamic therapy (PDT). The primary endpoint is OS and secondary outcomes are progression-free survival (PFS), OS and PFS with and without radiographically residual lesions as subgroups, OS and PFS with and without PDT, p53-negative OS and PFS, high Cluster of Differentiation-8 score OS and PFS, OS associated with death in primary disease, and 24-month OS and PFS rates. All institutions received ethical committee approval and patient enrollment began in 2021. Importance of the study Given the growing interest in immunotherapy (IMT), we developed an autologous formalin-fixed tumor vaccine (AFTV) manufactured from the patient’s own glioblastoma multiforme (GBM) tissue in paraffin-embedded blocks made from the resected tumor and a double-blind, randomized phase IIB trial of AFTV with temozolomide in newly diagnosed GBM was conducted. The 3-year progression-free survival (PFS) rate for patients with gross total resection (GTR) on imaging tended toward improvement: 81% in the AFTV group versus 46% in the placebo group (P = .067). Based on these IIB results, the feasibility of conducting a phase III trial was confirmed for IIB-eligible patients with total resection. We here plan to conduct the world’s first double-blind, randomized, placebo-controlled phase III trial using Cellm-001 to demonstrate autologous tumor immunostimulant efficacy. This IMT, in combination with sub-analyses (GTR, P53 status, CD8 score, and other factors) to be validated, is expected to be a breakthrough in effective standards of care for the treatment of GBM. Trial registration Registry number: jRCT2031200153; Date of Registration: 20 /October, /2020; Date of First Patient Enrollment: 14 /January/, 2021.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Device Engineering, Kobe University, Kusunoki-cho, Chuo-ku, Kobe City, Hyogo 650-0017, Japan.
- Department of Neurosurgery, Tokyo Women's Medical University, Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan.
- Institute of Advanced Biomedical Engineering and Science, Tokyo Women's Medical University, Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan.
- Department of Neurosurgery, University of Tsukuba, Tennodai, Tsukuba City, Ibaraki 305-8575, Japan.
- Department of Biostatistics, Institute of Medicine, University of Tsukuba, Tennodai, Tsukuba City, Ibaraki 305-8575, Japan.
- Tsukuba Clinical Research and Development Organization, University of Tsukuba, Tennodai, Tsukuba City, Ibaraki 305-8575, Japan.
ORCID-Profile: Manabu Tamura, Takakazu Kawamata, Masayuki Kanamori, Yoshiki Arakawa
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Muragaki, Y., Ishikawa, E., Tamura, M., Kawamata, T., Gosho, M., Hashimoto, K., Komori, T., Yokoo, H., Matsutani, M., Maebayashi, K., Tanaka, T., Yamaguchi, S., Kanamori, M., Yamamoto, T., Hanihara, M., Arakawa, Y., Sasayama, T., Abe, T., Nakamura, H., …, & Ohno, T. (2025). A randomized, placebo-controlled phase III trial of an autologous, formalin-fixed tumor vaccine for newly diagnosed glioblastoma: trial protocol. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyaf078
Vancouver
Muragaki Y, Ishikawa E, Tamura M, Kawamata T, Gosho M, Hashimoto K, et al. A randomized, placebo-controlled phase III trial of an autologous, formalin-fixed tumor vaccine for newly diagnosed glioblastoma: trial protocol. Japanese Journal of Clinical Oncology. 2025. doi:10.1093/jjco/hyaf078
BibTeX
@article{Muragaki2025,
author = {Muragaki, Yoshihiro and Ishikawa, Eiichi and Tamura, Manabu and Kawamata, Takakazu and Gosho, Masahiko and Hashimoto, Koichi and Komori, Takashi and Yokoo, Hideaki and Matsutani, Masao and Maebayashi, Katsuya and Tanaka, Toshihide and Yamaguchi, Shigeru and Kanamori, Masayuki and Yamamoto, Tetsuya and Hanihara, Mitsuto and Arakawa, Yoshiki and Sasayama, Takashi and Abe, Tatsuya and Nakamura, Hideo and Mukasa, Akitake and Uzuka, Takeo and Nakajo, Kosuke and Ohno, Tadao},
title = {A randomized, placebo-controlled phase III trial of an autologous, formalin-fixed tumor vaccine for newly diagnosed glioblastoma: trial protocol},
journal = {Japanese Journal of Clinical Oncology},
year = {2025},
doi = {10.1093/jjco/hyaf078}
}
EUVIMED